Login to Your Account



Clinic Roundup


Monday, August 8, 2011
Trius Therapeutics Inc., of San Diego, reached an agreement with the FDA, under the special protocol assessment (SPA) process, on the design of its second planned Phase III study for the intravenous and oral dosage forms of torezolid phosphate to treat acute bacterial skin and skin structure infections.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription